Leerink Partners Announces Innovative Therapeutics Research Model

Recent hires provide foundation for one of the largest therapeutics research teams in the industry.

BOSTON--()--Leerink Partners, a leading healthcare investment bank, announced today the completion of hiring for their new disease-focused Therapeutics Research team. The novel alignment by therapeutic area will allow research analysts to develop and maintain expertise in their respective areas; Mr. Schwartz (Rare Diseases), Dr. Foroohar (Genetic Medicines), Dr. Sarraf (Inflammation and Immunology), Mr. Goodman (Neurosciences), Dr. Graybosch (Immuno-oncology), Dr. Berens (Targeted Oncology), Dr. Chang (Emerging Oncology), Ms. Fadia (Women’s Health, Pain and Generics) and Dr. Porges (Diversified Biopharma).

This follows recent hiring announcements of five therapeutics analysts in the second quarter of 2018. The Therapeutics Research team is charged with elevating the firm’s therapeutics research coverage to be the deepest and broadest effort on the street. The expanded team is expected to cover over 180 companies to support the firm’s growing list of biopharmaceutical relationships.

“We are excited to have completed the build-out of our Therapeutics Research team,” commented Jeff Leerink, Chairman and CEO of Leerink Partners. “This further specialization reinforces our commitment to being the most knowledgeable research provider on the street.”

“Leerink’s Equity Research team has a demonstrated history of delivering unique and valuable insights to investors across every sector of healthcare,” stated John Sullivan, CFA, Senior Managing Director of Equity Research and Healthcare Investment Strategist at Leerink Partners. “This exceptional group of analysts has the resources and experience to fulfill our ambitious goals for our therapeutics research efforts.”

Geoffrey Porges, MBBS, Director of Therapeutics Research at Leerink Partners added, “As the biopharmaceutical industry rapidly evolves, and new products and technologies emerge at an accelerating pace, our disease -focused Therapeutics Research team will keep abreast of those changes and developments. Their focused attention and personal expertise should provide meaningful insights concerning even the most technically complex products, markets and stocks in the sector."

About Leerink Partners

Leerink Partners LLC is a leading investment bank, specializing in healthcare. Our knowledge, experience and focus enable us to help our clients define and achieve their strategic, capital markets and investment objectives. We partner with companies that develop and commercialize innovative products and services that are defining the future of healthcare. Leerink Partners LLC is a member of FINRA/SIPC. For more information, please visit: www.leerink.com.

Contacts

Leerink Partners
Diane Vieira, 617-918-4097
or
Weber Shandwick
617-520-7088

Release Summary

Leerink Partners announces the completion of hiring for their new, novel disease-focused Therapeutics Research team.

Contacts

Leerink Partners
Diane Vieira, 617-918-4097
or
Weber Shandwick
617-520-7088